On 21 September 2022, the RWE4Decisions community gathered for a multi-stakeholder discussion on HealthData in Germany, with a focus on the routine data collection practice (AbD) at the Federal Joint Committee (G-BA). The panel featured representation of HTA bodies, patients, insurers and industry.
This was the second public webinar to update on how countries are developing their data environments in a way that could be useful for HTA bodies and Payers, to support additional data collection.
PROGRAMME
15.00 Welcoming remarks from the co-moderators
Dr. Diane Kleinermans, President of the Commission of Drugs Reimbursement, National Institute of Health and Disability Insurance (INAMI-RIZIV), Belgium
Dr. Karen Facey, Evidence Based Health Policy Consultant, RWE4Decisions Secretariat
15.10 Keynote address
Dr. Antje Behring, Head of Pharmaceuticals Department, German Federal Joint Committee (G-BA)
15.30 Moderated discussion
Dr. Antje Behring, Head of Pharmaceuticals Department, German Federal Joint Committee (G-BA)
Dr. Martin Danner, Managing Director, Federal Association of Self-Help Organisations for people with disabilities and chronic diseases and their relatives (BAG Selbsthilfe)
Dr. Barthold Deiters, Head of Pharmaceuticals, Society for efficiency and quality in health insurance companies (GWQ ServicePlus AG)
Dr. Alexander Natz, Secretary General, European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)
Q&A with the audience
16.25 Closing remarks
Dr. Diane Kleinermans, President of the Commission of Drugs Reimbursement, National Institute of Health and Disability Insurance (INAMI-RIZIV), Belgium
16.30 Meeting close